Asia Pacific Point-of-Care Molecular Diagnostics Market

Historic Data: 2019-2020   |   Base Year: 2021   |   Forecast Period: 2022-2028

Analysis by Product & Services (Assays & Kits, Instruments, and Services & Software), Technology [PCR, Isothermal Nucleic Acid Amplification Technology (INAAT), and Other Technologies], Application (Infectious Diseases, Oncology, Hematology, Prenatal Testing, Endocrinology, and Other Applications), and End User (Hospitals & Clinics, Diagnostic Laboratories, Research & Academic Institutes, and Others)


No. of Pages: 208    |    Report Code: TIPRE00026189    |    Category: Life Sciences

Available Report Formats

pdf-format excel-format pptx-format
Buy Now
Asia Pacific Point-of-Care Molecular Diagnostics Market

According to our new research study on “Asia Pacific Point-of-Care Molecular Diagnostics Market to 2028 – Regional Analysis and Forecast – by Product & Services, Technology, Application, and End User,” the market is projected to reach US$ 1,251.67 million by 2028 from US$ 499.19 million in 2021; it is expected to grow at a CAGR of 14.0% from 2022 to 2028.

The growth of the market is primarily attributed to the growing demand for specific viral detection methods that consume less time for timely infection control and rising incidence of infectious diseases. Moreover, rising R&D and innovation in Asia Pacific point-of-care molecular diagnostics are expected to foster the market growth during the forecast period. However, the pricing pressures owing to reimbursement cuts hinder the market growth. The COVID-19 pandemic has had a significant positive impact on the point-of-care molecular diagnostic market. Amid the pandemic, the increased demand for diagnostic kits for the rapid detection of COVID-19 boosted the adoption of point-of-care testing across the world. The rising number of COVID-19 cases and growing pressure on various governments across the world to improve patient management have boosted the demand for rapid antigen testing kits that can be effectively used in point-of-care settings.

Based on product & services, the Asia Pacific point-of-care molecular diagnostics market is segmented into assays & kits, instruments, and services & software. The assays & kits segment leads the market and is expected to register the highest CAGR during the forecast period. Based on technology, the Asia Pacific point-of-care molecular diagnostics market is segmented into PCR, isothermal nucleic acid amplification technology (INAAT), and other technologies. The PCR segment leads the market, whereas the isothermal nucleic acid amplification technology (INAAT) segment is expected to register the highest CAGR during the forecast period. By application, the Asia Pacific point-of-care molecular diagnostics market is segmented into infectious diseases, oncology, hematology, prenatal testing, endocrinology, and other applications. The infectious diseases segment holds the largest share of the Asia Pacific point-of-care molecular diagnostics market. However, the oncology segment is anticipated to register the highest CAGR in the market during the forecast period. By end user, the Asia Pacific point-of-care molecular diagnostics market is segmented into hospitals & clinics, diagnostic laboratories, research & academic institutes, and others. The diagnostic laboratories segment leads the market and is estimated to register the highest CAGR in the market during the forecast period. 

Point-of-care (POC) molecular tests are accurate and scalable that increase the scope for the diagnosis of diseases, which can be done in the community and outside the laboratory setting. Compared with laboratory testing, point-of-care molecular diagnostics provides various advantages such as fewer clinic visits, shorter hospital stays, better drug therapy optimization, and less inappropriate drug use. The healthcare sector is undergoing huge transformation due to the emergence of new and effective technologies across the sector. Thus, the growing demand for effective diagnostics that consumes less time than laboratory testing drives the demand for POC molecular assays and kits propelling the growth of Asia Pacific point-of-care molecular diagnostics market over the forecast period. 

The World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), and International Agency for Research on Cancer are a few of the primary and secondary sources referred to while preparing the report on the Asia Pacific point-of-care molecular diagnostics market.


Asia Pacific Point-of-Care Molecular Diagnostics Strategic Insights

Strategic insights for the Asia Pacific Point-of-Care Molecular Diagnostics provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

strategic-framework/asia-pacific-point-of-care-molecular-diagnostics-market-strategic-framework.webp
Get more information on this report

Asia Pacific Point-of-Care Molecular Diagnostics Report Scope

Report Attribute Details
Market size in 2021 US$ 499.19 Million
Market Size by 2028 US$ 1,251.67 Million
Global CAGR (2022 - 2028) 14.0%
Historical Data 2019-2020
Forecast period 2022-2028
Segments Covered By Product & Services
  • Assays & Kits
  • Instruments
  • Services & Software
By Technology
  • PCR
  • Isothermal Nucleic Acid Amplification Technology
  • Other Technologies
By Application
  • Infectious Diseases
  • Oncology
  • Hematology
  • Prenatal Testing
  • Endocrinology
  • Other Applications
By End User
  • Hospitals & Clinics
  • Diagnostic Laboratories
  • Research & Academic Institutes
Regions and Countries Covered Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
Market leaders and key company profiles
  • bioMérieux SA
  • F. Hoffmann-La Roche Ltd.
  • Danaher Corporation
  • Enzo Biochem, Inc.
  • Abbott
  • binx health, Inc.
  • Meridian BioScience, Inc.
  • Biocartis
  • Quidel Corporation
  • Bio-Rad Laboratories, Inc.
  • Get more information on this report

    Asia Pacific Point-of-Care Molecular Diagnostics Regional Insights

    The geographic scope of the Asia Pacific Point-of-Care Molecular Diagnostics refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.

    geography/asia-pacific-point-of-care-molecular-diagnostics-market-geography.webp
    Get more information on this report

    The List of Companies - Asia Pacific Point-of-Care Molecular Diagnostics Market

    1. bioMérieux SA
    2.  F. Hoffmann-La Roche Ltd.
    3. Danaher Corporation
    4.  Enzo Biochem, Inc.
    5. Abbott
    6. binx health, Inc.
    7. Meridian BioScience, Inc.
    8. Biocartis
    9. Quidel Corporation
    10. Bio-Rad Laboratories, Inc.
    Frequently Asked Questions
    How big is the Asia Pacific Point-of-Care Molecular Diagnostics Market?

    The Asia Pacific Point-of-Care Molecular Diagnostics Market is valued at US$ 499.19 Million in 2021, it is projected to reach US$ 1,251.67 Million by 2028.

    What is the CAGR for Asia Pacific Point-of-Care Molecular Diagnostics Market by (2022 - 2028)?

    As per our report Asia Pacific Point-of-Care Molecular Diagnostics Market, the market size is valued at US$ 499.19 Million in 2021, projecting it to reach US$ 1,251.67 Million by 2028. This translates to a CAGR of approximately 14.0% during the forecast period.

    What segments are covered in this report?

    The Asia Pacific Point-of-Care Molecular Diagnostics Market report typically cover these key segments-

    • Product & Services (Assays & Kits, Instruments, Services & Software)
    • Technology (PCR, Isothermal Nucleic Acid Amplification Technology, Other Technologies)
    • Application (Infectious Diseases, Oncology, Hematology, Prenatal Testing, Endocrinology, Other Applications)
    • End User (Hospitals & Clinics, Diagnostic Laboratories, Research & Academic Institutes)

    What is the historic period, base year, and forecast period taken for Asia Pacific Point-of-Care Molecular Diagnostics Market?

    The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Asia Pacific Point-of-Care Molecular Diagnostics Market report:

  • Historic Period : 2019-2020
  • Base Year : 2021
  • Forecast Period : 2022-2028
  • Who are the major players in Asia Pacific Point-of-Care Molecular Diagnostics Market?

    The Asia Pacific Point-of-Care Molecular Diagnostics Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:

  • bioMérieux SA
  • F. Hoffmann-La Roche Ltd.
  • Danaher Corporation
  • Enzo Biochem, Inc.
  • Abbott
  • binx health, Inc.
  • Meridian BioScience, Inc.
  • Biocartis
  • Quidel Corporation
  • Bio-Rad Laboratories, Inc.
  • Who should buy this report?

    The Asia Pacific Point-of-Care Molecular Diagnostics Market report is valuable for diverse stakeholders, including:

    • Investors: Provides insights for investment decisions pertaining to market growth, companies, or industry insights. Helps assess market attractiveness and potential returns.
    • Industry Players: Offers competitive intelligence, market sizing, and trend analysis to inform strategic planning, product development, and sales strategies.
    • Suppliers and Manufacturers: Helps understand market demand for components, materials, and services related to concerned industry.
    • Researchers and Consultants: Provides data and analysis for academic research, consulting projects, and market studies.
    • Financial Institutions: Helps assess risks and opportunities associated with financing or investing in the concerned market.

    Essentially, anyone involved in or considering involvement in the Asia Pacific Point-of-Care Molecular Diagnostics Market value chain can benefit from the information contained in a comprehensive market report.